



## Clinical trial results:

### A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects with Moderate to Severe Ulcerative Colitis (FIGARO UC 302)

#### Summary

EudraCT number	2017-000572-28
Trial protocol	IE HU SK BG GR BE ES PT FR
Global end of trial date	06 October 2020

#### Results information

Result version number	v1 (current)
This version publication date	12 April 2021
First version publication date	12 April 2021

#### Trial information

##### Trial identification

Sponsor protocol code	SHP647-302
-----------------------	------------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03259308
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	Shire
Sponsor organisation address	300 ShireWay, Lexington, United States, MA 02421
Public contact	Study Director, Shire, ClinicalTransparency@takeda.com
Scientific contact	Study Director, Shire, ClinicalTransparency@takeda.com

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	06 October 2020
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	06 October 2020
Was the trial ended prematurely?	Yes

Notes:

## General information about the trial

Main objective of the trial:

The primary objective of this study was to evaluate the efficacy of ontamalimab in inducing remission, based on composite score of subject reported symptoms and centrally read endoscopy, in subjects with moderate to severe Ulcerative Colitis (UC).

Protection of trial subjects:

This study was conducted in accordance with International Council for Harmonisation (ICH) Good Clinical Practice (GCP) Guideline E6 (1996), the principles of the Declaration of Helsinki, as well as other applicable local ethical and legal requirements.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	05 December 2017
Long term follow-up planned	Yes
Long term follow-up rationale	Safety
Long term follow-up duration	4 Months
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Argentina: 1
Country: Number of subjects enrolled	Belgium: 3
Country: Number of subjects enrolled	Bosnia and Herzegovina: 2
Country: Number of subjects enrolled	Bulgaria: 24
Country: Number of subjects enrolled	Canada: 4
Country: Number of subjects enrolled	Colombia: 6
Country: Number of subjects enrolled	Estonia: 1
Country: Number of subjects enrolled	Greece: 1
Country: Number of subjects enrolled	Hungary: 28
Country: Number of subjects enrolled	Ireland: 1
Country: Number of subjects enrolled	Japan: 16
Country: Number of subjects enrolled	Korea, Republic of: 17
Country: Number of subjects enrolled	Lebanon: 1
Country: Number of subjects enrolled	Mexico: 14
Country: Number of subjects enrolled	New Zealand: 3
Country: Number of subjects enrolled	Portugal: 8
Country: Number of subjects enrolled	Slovakia: 15

Country: Number of subjects enrolled	Spain: 5
Country: Number of subjects enrolled	Switzerland: 1
Country: Number of subjects enrolled	Ukraine: 77
Country: Number of subjects enrolled	United States: 51
Worldwide total number of subjects	279
EEA total number of subjects	86

Notes:

---

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	1
Adults (18-64 years)	258
From 65 to 84 years	20
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

The study was conducted at 205 sites between 5 December 2017 (first subject first visit) and 06 October 2020 (last subject last visit).

### Pre-assignment

Screening details:

A total of 279 subjects were enrolled and randomized in this study.

### Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Placebo

Arm description:

Subjects received placebo matched to ontamalimab subcutaneous (SC) injection, using a prefilled syringe (PFS) on Week 0, Week 4, and Week 8 in a 12-week treatment period.

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Subjects received placebo matched to ontamalimab SC injection, using a PFS.

<b>Arm title</b>	Ontamalimab 25 mg
------------------	-------------------

Arm description:

Subjects received 25 milligrams (mg) of ontamalimab SC injection, using a PFS on Week 0, Week 4 and Week 8 in a 12-week treatment period.

Arm type	Experimental
Investigational medicinal product name	Ontamalimab
Investigational medicinal product code	SHP647
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Subjects received 25 mg of ontamalimab SC injection, using a PFS.

<b>Arm title</b>	Ontamalimab 75 mg
------------------	-------------------

Arm description:

Subjects received 75 mg of ontamalimab SC injection, using a PFS on Week 0, Week 4 and Week 8 in a 12-week treatment period.

Arm type	Experimental
----------	--------------

Investigational medicinal product name	Ontamalimab
Investigational medicinal product code	SHP647
Other name	
Pharmaceutical forms	Solution for injection
Routes of administration	Subcutaneous use

Dosage and administration details:

Subjects received 75 mg of ontamalimab SC injection, using a PFS.

<b>Number of subjects in period 1</b>	Placebo	Ontamalimab 25 mg	Ontamalimab 75 mg
Started	56	111	112
Completed	49	103	105
Not completed	7	8	7
Consent withdrawn by subject	2	1	3
Adverse event, non-fatal	5	4	1
Protocol Deviation	-	3	-
Pregnancy	-	-	1
Lost to follow-up	-	-	1
Lack of efficacy	-	-	1

## Baseline characteristics

### Reporting groups

Reporting group title	Placebo
Reporting group description: Subjects received placebo matched to ontamalimab subcutaneous (SC) injection, using a prefilled syringe (PFS) on Week 0, Week 4, and Week 8 in a 12-week treatment period.	
Reporting group title	Ontamalimab 25 mg
Reporting group description: Subjects received 25 milligrams (mg) of ontamalimab SC injection, using a PFS on Week 0, Week 4 and Week 8 in a 12-week treatment period.	
Reporting group title	Ontamalimab 75 mg
Reporting group description: Subjects received 75 mg of ontamalimab SC injection, using a PFS on Week 0, Week 4 and Week 8 in a 12-week treatment period.	

Reporting group values	Placebo	Ontamalimab 25 mg	Ontamalimab 75 mg
Number of subjects	56	111	112
Age categorical Units:			

Age Continuous Units: years arithmetic mean standard deviation	41.6 ± 13.50	43.5 ± 14.16	43.9 ± 13.08
Sex: Female, Male Units: Subjects			
Female	23	46	45
Male	33	65	67
Race, Customized Units: Subjects			
American Indian or Alaska Native	0	5	3
Asian: Japanese	6	5	6
Asian: Korean	4	5	8
Asian: Other	1	0	0
Black or African American	2	4	1
White	41	85	88
Native Hawaiian or Other Pacific Islander	0	1	0
Multiple	1	5	1
Other (Unspecified)	1	1	5
Ethnicity (NIH/OMB) Units: Subjects			
Hispanic or Latino	5	17	16
Not Hispanic or Latino	51	93	96
Unknown or Not Reported	0	1	0

Reporting group values	Total		
Number of subjects	279		

Age categorical Units:			
Age Continuous Units: years arithmetic mean standard deviation	-		
Sex: Female, Male Units: Subjects			
Female	114		
Male	165		
Race, Customized Units: Subjects			
American Indian or Alaska Native	8		
Asian: Japanese	17		
Asian: Korean	17		
Asian: Other	1		
Black or African American	7		
White	214		
Native Hawaiian or Other Pacific Islander	1		
Multiple	7		
Other (Unspecified)	7		
Ethnicity (NIH/OMB) Units: Subjects			
Hispanic or Latino	38		
Not Hispanic or Latino	240		
Unknown or Not Reported	1		

## End points

### End points reporting groups

Reporting group title	Placebo
Reporting group description: Subjects received placebo matched to ontamalimab subcutaneous (SC) injection, using a prefilled syringe (PFS) on Week 0, Week 4, and Week 8 in a 12-week treatment period.	
Reporting group title	Ontamalimab 25 mg
Reporting group description: Subjects received 25 milligrams (mg) of ontamalimab SC injection, using a PFS on Week 0, Week 4 and Week 8 in a 12-week treatment period.	
Reporting group title	Ontamalimab 75 mg
Reporting group description: Subjects received 75 mg of ontamalimab SC injection, using a PFS on Week 0, Week 4 and Week 8 in a 12-week treatment period.	

### Primary: Number of Subjects With Remission Based on Composite Score at Week 12

End point title	Number of Subjects With Remission Based on Composite Score at Week 12
End point description: Remission was defined as a composite score of patient-reported symptoms using daily e-diary and centrally read endoscopy as stool frequency sub-score of 0 or 1 with at least a 1-point change from baseline, rectal bleeding sub-score of 0 and endoscopic sub-score of 0 or 1 (modified, excluded friability). The composite score was a recommended measure derived from the Mayo score without the physician global assessment (PGA) sub-score and ranged from 0 to 9 points. The Mayo score was a measure of Ulcerative Colitis (UC) disease activity. It ranged from 0 to 12 points and consisted of 4 sub-scores, each graded from 0 to 3 with higher scores indicating more severe disease. The sub-scores were stool frequency (0-3); rectal bleeding (0-3); findings of endoscopy (0-3); physician global assessment (0-3). Full analysis set (FAS) consisted of all subjects in the randomized set who had received at least 1 dose of investigational product (IP).	
End point type	Primary
End point timeframe: At Week 12	

End point values	Placebo	Ontamalimab 25 mg	Ontamalimab 75 mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	56	111	112	
Units: Subjects	7	30	33	

### Statistical analyses

Statistical analysis title	Statistical analysis 1
Comparison groups	Placebo v Ontamalimab 25 mg



Number of subjects included in analysis	167
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.027 <sup>[1]</sup>
Method	Cochran-Mantel-Haenszel

Notes:

[1] - P-value was based on Cochran-Mantel-Haenszel chi-square test stratified by actual status of prior anti-TNF treatment and glucocorticoid at baseline.

<b>Statistical analysis title</b>	Statistical analysis 2
Comparison groups	Placebo v Ontamalimab 75 mg
Number of subjects included in analysis	168
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.014 <sup>[2]</sup>
Method	Cochran-Mantel-Haenszel

Notes:

[2] - P-value was based on Cochran-Mantel-Haenszel chi-square test stratified by actual status of prior anti-TNF treatment and glucocorticoid at baseline.

## Secondary: Number of Subjects With Endoscopic Remission at Week 12

End point title	Number of Subjects With Endoscopic Remission at Week 12
End point description:	
Endoscopic remission was defined by centrally read endoscopic sub-score 0 or 1 (modified, excluded friability). The centrally read endoscopic sub-score of Mayo score ranged from 0 to 3 with higher scores indicating more severe disease. FAS consisted of all subjects in the randomized set who had received at least 1 dose of IP.	
End point type	Secondary
End point timeframe:	
At Week 12	

End point values	Placebo	Ontamalimab 25 mg	Ontamalimab 75 mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	56	111	112	
Units: Subjects	7	39	38	

## Statistical analyses

<b>Statistical analysis title</b>	Statistical analysis 1
Comparison groups	Placebo v Ontamalimab 25 mg
Number of subjects included in analysis	167
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.001 <sup>[3]</sup>
Method	Cochran-Mantel-Haenszel

Notes:

[3] - P-value was based on Cochran-Mantel-Haenszel chi-square test stratified by actual status of prior anti-TNF treatment and glucocorticoid at baseline.

<b>Statistical analysis title</b>	Statistical analysis 2
Comparison groups	Placebo v Ontamalimab 75 mg
Number of subjects included in analysis	168
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.003 <sup>[4]</sup>
Method	Cochran-Mantel-Haenszel

Notes:

[4] - P-value was based on Cochran-Mantel-Haenszel chi-square test stratified by actual status of prior anti-TNF treatment and glucocorticoid at baseline.

### Secondary: Number of Subjects With Clinical Remission at Week 12

End point title	Number of Subjects With Clinical Remission at Week 12
End point description: Clinical remission was defined by stool frequency sub-score of 0 or 1 with at least a 1-point change from baseline in stool frequency sub-score, and rectal bleeding sub-score of 0. The stool frequency sub-score and rectal bleeding sub-score ranged from 0 to 3 with higher scores indicating more severe disease. FAS consisted of all subjects in the randomized set who had received at least 1 dose of IP.	
End point type	Secondary
End point timeframe: At Week 12	

End point values	Placebo	Ontamalimab 25 mg	Ontamalimab 75 mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	56	111	112	
Units: Subjects	10	50	56	

### Statistical analyses

<b>Statistical analysis title</b>	Statistical analysis 1
Comparison groups	Placebo v Ontamalimab 25 mg
Number of subjects included in analysis	167
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001 <sup>[5]</sup>
Method	Cochran-Mantel-Haenszel

Notes:

[5] - P-value was based on Cochran-Mantel-Haenszel chi-square test stratified by actual status of prior anti-TNF treatment and glucocorticoid at baseline.

<b>Statistical analysis title</b>	Statistical analysis 2
Comparison groups	Placebo v Ontamalimab 75 mg

Number of subjects included in analysis	168
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001 <sup>[6]</sup>
Method	Cochran-Mantel-Haenszel

Notes:

[6] - P-value was based on Cochran-Mantel-Haenszel chi-square test stratified by actual status of prior anti-TNF treatment and glucocorticoid at baseline.

## Secondary: Number of Subjects With Clinical Response Based on Composite Score at Week 12

End point title	Number of Subjects With Clinical Response Based on Composite Score at Week 12
-----------------	---

End point description:

Clinical response based on composite score was defined as a decrease from baseline in the composite score of patient-reported symptoms using daily e-diary and centrally read endoscopy of at least 2 points and at least 30 percent (%), with an accompanying decrease in the sub-score for rectal bleeding greater than or equal to ( $\geq$ ) 1 point or a sub-score for rectal bleeding less than or equal to ( $\leq$ ) 1. The composite score was a recommended measure derived from the Mayo score without the PGA sub-score and ranged from 0 to 9 points. The Mayo score was a measure of UC disease activity. It ranged from 0 to 12 points and consisted of 4 sub-scores, each graded from 0 to 3 with higher scores indicating more severe disease. The sub-scores were stool frequency (0-3); rectal bleeding (0-3); findings of endoscopy (0-3); PGA (0-3). FAS consisted of all subjects in the randomized set who had received at least 1 dose of IP.

End point type	Secondary
----------------	-----------

End point timeframe:

At Week 12

End point values	Placebo	Ontamalimab 25 mg	Ontamalimab 75 mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	56	111	112	
Units: Subjects	16	67	64	

## Statistical analyses

<b>Statistical analysis title</b>	Statistical analysis 2
Comparison groups	Placebo v Ontamalimab 75 mg
Number of subjects included in analysis	168
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001 <sup>[7]</sup>
Method	Cochran-Mantel-Haenszel

Notes:

[7] - P-value was based on Cochran-Mantel-Haenszel chi-square test stratified by actual status of prior anti-TNF treatment and glucocorticoid at baseline.

<b>Statistical analysis title</b>	Statistical analysis 1
Comparison groups	Placebo v Ontamalimab 25 mg

Number of subjects included in analysis	167
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001 <sup>[8]</sup>
Method	Cochran-Mantel-Haenszel

Notes:

[8] - P-value was based on Cochran-Mantel-Haenszel chi-square test stratified by actual status of prior anti-TNF treatment and glucocorticoid at baseline.

## Secondary: Number of Subjects With Mucosal Healing Based on Endoscopic and Histological Assessment Using the Geboes Score Grading System at Week 12

End point title	Number of Subjects With Mucosal Healing Based on Endoscopic and Histological Assessment Using the Geboes Score Grading System at Week 12
-----------------	--

End point description:

Mucosal healing was defined by centrally read endoscopic sub-score 0 or 1 (modified, excluded friability) and centrally read Geboes score of ≤2. The centrally read endoscopic sub-score of Mayo score ranged from 0 to 3 with higher scores indicating more severe disease. Geboes score grading system, was a validated score for evaluating histologic disease activity in UC as follows: grade 0 equal to (=) structural and architectural changes; grade 1 = chronic inflammatory infiltrate; grade 2 = lamina propria neutrophils and eosinophils; grade 3 = neutrophils in the epithelium; grade 4 = crypt destruction; grade 5 = erosions or ulceration. A higher Geboes score indicating more severe disease. Number of subjects with mucosal healing based on endoscopic and histological assessment using the Geboes score grading system were reported. FAS consisted of all subjects in the randomized set who had received at least 1 dose of IP.

End point type	Secondary
----------------	-----------

End point timeframe:

At Week 12

End point values	Placebo	Ontamalimab 25 mg	Ontamalimab 75 mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	56	111	112	
Units: Subjects	6	35	30	

## Statistical analyses

<b>Statistical analysis title</b>	Statistical analysis 1
Comparison groups	Placebo v Ontamalimab 25 mg
Number of subjects included in analysis	167
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.002 <sup>[9]</sup>
Method	Cochran-Mantel-Haenszel

Notes:

[9] - P-value was based on Cochran-Mantel-Haenszel chi-square test stratified by actual status of prior anti-TNF treatment and glucocorticoid at baseline.

<b>Statistical analysis title</b>	Statistical analysis 2
Comparison groups	Placebo v Ontamalimab 75 mg

Number of subjects included in analysis	168
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.017 <sup>[10]</sup>
Method	Cochran-Mantel-Haenszel

Notes:

[10] - P-value was based on Cochran-Mantel-Haenszel chi-square test stratified by actual status of prior anti-TNF treatment and glucocorticoid at baseline.

## Secondary: Number of Subjects With Remission Based on Total Mayo Score at Week 12

End point title	Number of Subjects With Remission Based on Total Mayo Score at Week 12
-----------------	--

End point description:

Remission was defined as a total Mayo score of  $\leq 2$  with no individual sub-score (stool frequency, rectal bleeding, endoscopy [modified, excluded friability], and PGA) exceeding 1, at the Week 12. The Total Mayo score ranged from 0 to 12 points and consisted of 4 sub-scores, each graded from 0 to 3 with higher scores indicating more severe disease: stool frequency (0-3); rectal bleeding (0-3); findings of endoscopy (0-3); PGA (0-3). FAS consisted of all subjects in the randomized set who had received at least 1 dose of IP.

End point type	Secondary
----------------	-----------

End point timeframe:

At Week 12

End point values	Placebo	Ontamalimab 25 mg	Ontamalimab 75 mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	56	111	112	
Units: Subjects	5	28	26	

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Subjects With Clinical Response Based on Total Mayo Score at Week 12

End point title	Number of Subjects With Clinical Response Based on Total Mayo Score at Week 12
-----------------	--

End point description:

Clinical response (Mayo) was defined as a decrease from baseline in the total Mayo score of at least 3 points and at least 30%, with an accompanying decrease in the sub-score for rectal bleeding  $\geq 1$  point or an absolute sub-score for rectal bleeding  $\leq 1$ . The Total Mayo score ranged from 0 to 12 points and consisted of the following 4 sub-scores, each graded from 0 to 3 with higher scores indicating more severe disease: stool frequency (0-3); rectal bleeding (0-3); findings of endoscopy (0-3); PGA (0-3). FAS consisted of all subjects in the randomized set who had received at least 1 dose of IP.

End point type	Secondary
----------------	-----------

End point timeframe:

At Week 12

End point values	Placebo	Ontamalimab 25 mg	Ontamalimab 75 mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	56	111	112	
Units: Subjects	19	66	63	

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Subjects With Partial Mayo Score $\leq 2$ With no Individual Sub-score Greater than ( $>$ ) 1 at Weeks 4, 8, and 12

End point title	Number of Subjects With Partial Mayo Score $\leq 2$ With no Individual Sub-score Greater than ( $>$ ) 1 at Weeks 4, 8, and 12
-----------------	---

End point description:

The partial Mayo score ranged from 0 to 9 points and consisted of the following 3 sub-scores, each graded from 0 to 3 with higher scores indicating more severe disease: Stool frequency (0-3); Rectal bleeding (0-3); PGA (0-3). The partial Mayo score did not include the endoscopy sub-score. FAS consisted of all subjects in the randomized set who had received at least 1 dose of IP.

End point type	Secondary
----------------	-----------

End point timeframe:

At Weeks 4, 8, and 12

End point values	Placebo	Ontamalimab 25 mg	Ontamalimab 75 mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	56	111	112	
Units: Subjects				
At Week 4	6	26	23	
At Week 8	12	53	41	
At Week 12	10	49	52	

### Statistical analyses

No statistical analyses for this end point

### Secondary: Number of Subjects With Clinical Remission With Stool Frequency Sub-scores of 0 or 1 and Rectal Bleeding Sub-score of 0 at Weeks 4 and 8

End point title	Number of Subjects With Clinical Remission With Stool Frequency Sub-scores of 0 or 1 and Rectal Bleeding Sub-score of 0 at Weeks 4 and 8
-----------------	--

End point description:

Number of subjects were reported who with stool frequency sub-scores of 0 or 1 and rectal bleeding

sub-score of 0. Clinical remission was defined as stool frequency sub-score of 0 or 1 with at least a 1-point change from baseline in stool frequency sub-score, and a rectal bleeding sub-score of 0. The stool frequency sub-score and rectal bleeding sub-score of Mayo score ranges from 0 to 3 with higher scores indicating more severe disease. FAS consisted of all subjects in the randomized set who had received at least 1 dose of IP.

End point type	Secondary
End point timeframe:	
At Weeks 4 and 8	

End point values	Placebo	Ontamalimab 25 mg	Ontamalimab 75 mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	56	111	112	
Units: Subjects				
At Week 4	4	28	22	
At Week 8	10	52	41	

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Subjects With Endoscopic Remission With Sub-score of 0 at Week 12

End point title	Number of Subjects With Endoscopic Remission With Sub-score of 0 at Week 12
-----------------	---

End point description:

Endoscopic remission was defined by centrally read endoscopic sub-score 0 (modified, excluded friability). The centrally read endoscopic sub-score of Mayo score ranged from 0 to 3 with higher scores indicating more severe disease. FAS consisted of all subjects in the randomized set who had received at least 1 dose of IP.

End point type	Secondary
End point timeframe:	
At Week 12	

End point values	Placebo	Ontamalimab 25 mg	Ontamalimab 75 mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	56	111	112	
Units: Subjects	1	14	14	

## Statistical analyses

No statistical analyses for this end point

---

**Secondary: Number of Subjects With Clinical Remission With Both Rectal Bleeding and Stool Frequency Sub-scores of 0 at Week 4, 8, and 12**

---

End point title	Number of Subjects With Clinical Remission With Both Rectal Bleeding and Stool Frequency Sub-scores of 0 at Week 4, 8, and 12
-----------------	---

End point description:

Number of subjects were reported with rectal bleeding and stool frequency sub-scores of 0. Clinical remission was defined as both rectal bleeding and stool frequency sub-scores of 0. The stool frequency sub-score and rectal bleeding sub-score of Mayo score ranges from 0 to 3 with higher scores indicating more severe disease. FAS consisted of all subjects in the randomized set who had received at least 1 dose of IP.

End point type	Secondary
----------------	-----------

End point timeframe:

At Week 4, 8, and 12

---

End point values	Placebo	Ontamalimab 25 mg	Ontamalimab 75 mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	56	111	112	
Units: Subjects				
At Week 4	0	15	12	
At Week 8	5	29	19	
At Week 12	6	36	26	

---

**Statistical analyses**

---

No statistical analyses for this end point

---

---

**Secondary: Number of Subjects With Deep Remission at Week 12**

---

End point title	Number of Subjects With Deep Remission at Week 12
-----------------	---

End point description:

Deep remission was defined as both endoscopic and rectal bleeding sub-scores of 0, and stool frequency sub-score  $\leq 1$  and a centrally read Geboes score of  $\leq 2$ . The stool frequency sub-score, rectal bleeding sub-score and endoscopic sub-score of Mayo score ranged from 0 to 3 with higher scores indicating more severe disease. The composite score was a recommended measure consisted of the Mayo score without the PGA sub-score and ranged from 0 to 9 points. Geboes score grading system was a validated score for evaluating histologic disease activity in UC as follows: grade 0 = structural and architectural changes; grade 1 = chronic inflammatory infiltrate; grade 2 = lamina propria neutrophils and eosinophils; grade 3 = neutrophils in the epithelium; grade 4 = crypt destruction; grade 5 = erosions or ulceration. A higher Geboes score indicating more severe disease. FAS consisted of all subjects in the randomized set who had received at least 1 dose of IP.

End point type	Secondary
----------------	-----------

End point timeframe:

At Week 12

---



End point values	Placebo	Ontamalimab 25 mg	Ontamalimab 75 mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	56	111	112	
Units: Subjects	1	11	9	

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change From Baseline in Average Worst Abdominal Pain Score Based on Patient Reported Outcome-ulcerative Colitis (PRO-UC) Daily e-Diary at Week 12

End point title	Change From Baseline in Average Worst Abdominal Pain Score Based on Patient Reported Outcome-ulcerative Colitis (PRO-UC) Daily e-Diary at Week 12
-----------------	---

End point description:

PRO-UC signs and symptom data were collected using a daily e-diary during treatment period. Collection of daily e-diary data was begun at least 10 days before the baseline visit. Subjects asked to record data of abdominal pain worst severity, over previous 24 hours, in the e-diary. Subjects signs and symptom average scores at each scheduled visit were calculated based on data recorded over most recent 3 days (consecutive or non-consecutive) of last 10 days prior to scheduled visit start date excluding following days: day of any bowel preparation, day of endoscopy, any days between day of bowel preparation and day of endoscopy and 2 days after day of endoscopy. Abdominal pain's worst severity assessment was based on 11-point numerical rating scale with 0-No pain and 10-Worst imaginable pain over the previous 24 hours. Higher scores indicating more severe pain. Analysis was performed using FAS. Here, number of subjects analysed signifies subjects who were evaluable for this endpoint.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Week 12

End point values	Placebo	Ontamalimab 25 mg	Ontamalimab 75 mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	47	104	107	
Units: Score on a scale				
least squares mean (standard error)	-1.69 (± 0.309)	-2.49 (± 0.218)	-1.83 (± 0.215)	

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change From Baseline in Diarrhea (Average Loose Bowel Movements) Score Based on PRO-UC Daily e-Diary at Week 12

End point title	Change From Baseline in Diarrhea (Average Loose Bowel Movements) Score Based on PRO-UC Daily e-Diary at Week 12
-----------------	---

End point description:

PRO-UC signs and symptom data were collected using a daily e-diary during treatment period. Collection of daily e-diary data was begun at least 10 days before the baseline visit. Subjects were asked to record

the signs and symptom data for number of loose bowel movement, as experienced over the previous 24 hours, in the e-diary. Subjects signs and symptom average scores at each scheduled visit were calculated based on data recorded over the most recent 3 days (consecutive or nonconsecutive) of the last 10 days prior to the scheduled visit start date excluding the following days: day of any bowel preparation, day of endoscopy, any days between day of bowel preparation and day of endoscopy, and the 2 days after the day of endoscopy. Average number of loose bowel movement ranged from 0-27. Higher scores indicating more frequent bowel movements. Analysis was performed using FAS. Here, number of subjects analysed signifies subjects who were evaluable for this endpoint.

End point type	Secondary
End point timeframe:	
Baseline, Week 12	

End point values	Placebo	Ontamalimab 25 mg	Ontamalimab 75 mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	47	104	107	
Units: Score on a Scale				
least squares mean (standard error)	-1.41 ( $\pm$ 0.405)	-3.50 ( $\pm$ 0.286)	-2.87 ( $\pm$ 0.284)	

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change From Baseline in Average Bowel Movements With Urgency Score Based on PRO-UC Daily e-Diary at Week 12 at Week 12

End point title	Change From Baseline in Average Bowel Movements With Urgency Score Based on PRO-UC Daily e-Diary at Week 12 at Week 12
-----------------	--

End point description:

PRO-UC signs and symptom data were collected using a daily e-diary during treatment period. Collection of daily e-diary data was begun at least 10 days before the baseline visit. Subjects were asked to record the signs and symptom data for number of bowel movement with urgency, as experienced over the previous 24 hours. Subjects signs and symptom average scores at each scheduled visit were calculated based on data recorded over the most recent 3 days (consecutive or nonconsecutive) of the last 10 days prior to the scheduled visit start date excluding the following days: day of any bowel preparation, day of endoscopy, any days between day of bowel preparation and day of endoscopy, and the 2 days after the day of endoscopy. Average number bowel movements urgency ranged from 0-27. Higher scores indicating more frequent bowel movements. Analysis was performed using FAS. Here, number of subjects analysed signifies subjects who were evaluable for this endpoint.

End point type	Secondary
End point timeframe:	
Baseline, Week 12	

End point values	Placebo	Ontamalimab 25 mg	Ontamalimab 75 mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	47	104	107	
Units: Score on a Scale				
least squares mean (standard error)	-1.09 (± 0.373)	-2.87 (± 0.263)	-2.56 (± 0.264)	

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change From Baseline in Absolute Stool Frequency (Average Number of Bowel Movements) Score Based on PRO-UC Daily e-Diary at Week 12

End point title	Change From Baseline in Absolute Stool Frequency (Average Number of Bowel Movements) Score Based on PRO-UC Daily e-Diary at Week 12
-----------------	---

End point description:

PRO-UC signs and symptom data were collected using a daily e-diary during treatment period. Collection of daily e-diary data was begun at least 10 days before the baseline visit. Subjects were asked to record the signs and symptom data for average number of bowel movements, as experienced over the previous 24 hours. Subjects signs and symptom average scores at each scheduled visit were calculated based on data recorded over the most recent 3 days (consecutive or nonconsecutive) of the last 10 days prior to the scheduled visit start date excluding the following days: day of any bowel preparation, day of endoscopy, any days between day of bowel preparation and day of endoscopy, and the 2 days after the day of endoscopy. Average number bowel movements ranged from 0-27. Higher scores indicating more frequent bowel movements. Analysis was performed using FAS. Here, number of subjects analysed signifies subjects who were evaluable for this endpoint.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Week 12

End point values	Placebo	Ontamalimab 25 mg	Ontamalimab 75 mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	47	104	107	
Units: Score on a Scale				
least squares mean (standard error)	-1.26 (± 0.386)	-3.32 (± 0.272)	-2.97 (± 0.272)	

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change From Baseline in Absolute Rectal Bleeding (Average Number Bowel Movements With Blood) Score Based on PRO-UC Daily e-Diary at Week 12

End point title	Change From Baseline in Absolute Rectal Bleeding (Average Number Bowel Movements With Blood) Score Based on PRO-UC Daily e-Diary at Week 12
-----------------	---

---

**End point description:**

PRO-UC signs and symptom data were collected using a daily e-diary during treatment period. Collection of daily e-diary data was begun at least 10 days before the baseline visit. Subjects asked to record data for average number of bowel movements with blood, as experienced over the previous 24 hours. Subjects signs and symptom average scores at each scheduled visit were calculated based on data recorded over the most recent 3 days (consecutive or nonconsecutive) of the last 10 days prior to the scheduled visit start date excluding the following days: day of any bowel preparation, day of endoscopy, any days between day of bowel preparation and day of endoscopy, and the 2 days after the day of endoscopy. Average number bowel movements with blood ranged from 0 to 27. Higher scores indicating more frequent bowel movements with blood. Analysis was performed using FAS. Here, number of subjects analysed signifies subjects who were evaluable for this endpoint.

---

End point type	Secondary
----------------	-----------

---

End point timeframe:

Baseline, Week 12

---

End point values	Placebo	Ontamalimab 25 mg	Ontamalimab 75 mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	47	104	107	
Units: Score on a Scale				
least squares mean (standard error)	-2.05 ( $\pm$ 0.379)	-3.74 ( $\pm$ 0.267)	-3.41 ( $\pm$ 0.265)	

---

**Statistical analyses**

No statistical analyses for this end point

---

---

**Secondary: Change From Baseline in Total Sign/Symptom Score Based on PRO-UC Daily e-Diary at Week 12**

---

End point title	Change From Baseline in Total Sign/Symptom Score Based on PRO-UC Daily e-Diary at Week 12
-----------------	---

---

**End point description:**

Total sign/symptom score was the average of the average scores of worst abdominal pain over the past 24 hours and the conversion scale values for number of bowel movements blood, number of bowel movements with urgency, number of bowel movements and number of loose bowel movements, with scale ranged of 0-10, with higher scores indicating higher severity. FAS consisted of all subjects in the randomized set who had received at least 1 dose of IP. Here, number of subjects analysed signifies subjects who were evaluable for this endpoint.

---

End point type	Secondary
----------------	-----------

---

End point timeframe:

Baseline, Week 12

---

End point values	Placebo	Ontamalimab 25 mg	Ontamalimab 75 mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	47	104	107	
Units: Score on a Scale				
least squares mean (standard error)	-1.15 ( $\pm$ 0.246)	-2.32 ( $\pm$ 0.173)	-2.00 ( $\pm$ 0.172)	

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Domains Scores at Weeks 8 and 12

End point title	Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Domains Scores at Weeks 8 and 12
End point description:	
IBDQ was a psychometrically validated PRO instrument for measuring the disease-specific health-related quality of life (HRQL) in subjects with inflammatory bowel disease, including UC. The IBDQ consisted of 32 items, which were grouped into 4 dimensions: bowel function, emotional status, systemic symptoms, and social function. The 4 domains were scored as follows: Bowel symptoms (BS): 10 to 70; Systemic symptoms (SS): 5 to 35; Emotional function (EF): 12 to 84; Social function (SF): 5 to 35. Higher scores indicating a better quality of life. FAS consisted of all subjects in the randomized set who had received at least 1 dose of IP. Here, number of subjects analysed signifies subjects who were evaluable for this endpoint and n=number analysed refer to subjects evaluable at specific time point.	
End point type	Secondary
End point timeframe:	
Baseline, Weeks 8 and 12	

End point values	Placebo	Ontamalimab 25 mg	Ontamalimab 75 mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	53	108	106	
Units: Score on a Scale				
least squares mean (standard error)				
BF: Change at Week 8 (n=53, 108, 106)	9.59 (± 1.611)	16.66 (± 1.189)	15.36 (± 1.180)	
BF: Change at Week 12 (n=50, 104, 106)	9.51 (± 1.707)	17.71 (± 1.250)	15.86 (± 1.232)	
ES: Change at Week 8 (n=53, 108, 106)	8.91 (± 1.701)	15.18 (± 1.255)	14.41 (± 1.247)	
ES: Change at Week 12 (n=50, 104, 106)	9.94 (± 1.861)	14.84 (± 1.359)	14.73 (± 1.341)	
SS: Change at Week 8 (n=53, 108, 106)	3.84 (± 0.759)	6.61 (± 0.561)	5.86 (± 0.557)	
SS: Change at Week 12 (n=50, 104, 106)	3.85 (± 0.814)	7.34 (± 0.596)	6.04 (± 0.587)	
SF: Change at Week 8 (n=53, 108, 106)	5.06 (± 0.873)	6.97 (± 0.643)	6.75 (± 0.640)	
SF: Change at Week 12 (n=50, 104, 106)	5.09 (± 0.926)	7.68 (± 0.677)	7.03 (± 0.668)	

## Statistical analyses

**Secondary: Change From Baseline in Total Scores in IBDQ at Weeks 8 and 12**

End point title	Change From Baseline in Total Scores in IBDQ at Weeks 8 and 12
-----------------	--

## End point description:

IBDQ was a psychometrically validated PRO instrument for measuring the disease-specific HRQL in subjects with inflammatory bowel disease, included UC. The IBDQ consisted of 32 items, which were grouped into 4 dimensions: bowel function, emotional status, systemic symptoms, and social function. The 4 domains were scored as follows: Bowel symptoms: 10 to 70; Systemic symptoms: 5 to 35; Emotional function: 12 to 84; Social function: 5 to 35. The total IBDQ score ranged from 32 to 224. For the total score and each domain, a higher score indicating better HRQL. A score of at least 170 corresponds to clinical remission and an increase of at least 16 points was considered to indicate a clinically meaningful improvement. FAS: all subjects in the randomized set who had received at least 1 dose of IP. Here, number of subjects analysed signifies subjects who were evaluable for this endpoint and n=number analysed refer to subjects evaluable at specific time point.

End point type	Secondary
----------------	-----------

## End point timeframe:

Baseline, Weeks 8 and 12

End point values	Placebo	Ontamalimab 25 mg	Ontamalimab 75 mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	53	108	106	
Units: Score on a Scale				
least squares mean (standard error)				
Change at Week 8 (n=53, 108, 106)	27.56 (± 4.574)	45.63 (± 3.380)	42.58 (± 3.358)	
Change at Week 12 (n=50, 104, 106)	28.39 (± 4.990)	47.75 (± 3.649)	43.85 (± 3.604)	

**Statistical analyses**

No statistical analyses for this end point

**Secondary: Change From Baseline in Short Form-36 Health Survey (SF-36), Version 2, Acute (Physical and Mental Component Summary Scores) at Week 12**

End point title	Change From Baseline in Short Form-36 Health Survey (SF-36), Version 2, Acute (Physical and Mental Component Summary Scores) at Week 12
-----------------	---

## End point description:

SF-36 was a generic quality-of-life instrument that had been widely used to assess HRQL of subjects. SF-36 consisted of 36 items that were aggregated into 8 multi-item scales (physical functioning [1=yes, limited a lot to 3=no, not limited at all], role-physical [1=all of the time to 5=none of the time], bodily pain [1=very severe to 6=none], general health [1=poor to 5=excellent], vitality [1=none of the time to 5=all of the time], social functioning [1=all of the time to 5=none of the time], role emotional [1=all of the time to 5=none of the time] and mental health [1=all of the time to 5=none of the time]). Four domains; PCS score (physical functioning, role-physical, bodily pain, general health) and MCS score (vitality, social functioning, role-emotional, mental health). Scores ranged from 0 to 100. Higher scores indicating better HRQL. Analysis was performed using FAS. Here, number of subjects analysed signifies subjects who were evaluable for this endpoint.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Week 12

End point values	Placebo	Ontamalimab 25 mg	Ontamalimab 75 mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	50	104	106	
Units: Score on a Scale				
least squares mean (standard error)				
Mental Component: Change at Week 12	2.09 (± 1.301)	7.37 (± 0.949)	6.68 (± 0.935)	
Physical Component: Change at Week 12	4.84 (± 0.982)	6.45 (± 0.721)	5.54 (± 0.709)	

### Statistical analyses

No statistical analyses for this end point

### Secondary: Change From Baseline in Short Form-36 Health Survey (SF-36), Version 2, Acute (Individual Domain Scores) at Week 12

End point title	Change From Baseline in Short Form-36 Health Survey (SF-36), Version 2, Acute (Individual Domain Scores) at Week 12
-----------------	---

End point description:

SF-36 was a generic quality-of-life instrument that had been widely used to assess HRQL of subjects. Generic instruments were used in general populations to assess a wide range of domains applicable to a variety of health states, conditions, and diseases. SF-36 consisted of 36 items that were aggregated into 8 multi-item scales (physical functioning [1=yes, limited a lot to 3=no, not limited at all], role-physical [1=all of the time to 5=none of the time], bodily pain [1=very severe to 6=none], general health [1=poor to 5=excellent], vitality [1=none of the time to 5=all of the time], social functioning [1=all of the time to 5=none of the time], role emotional [1=all of the time to 5=none of the time] and mental health [1=all of the time to 5=none of the time]), with scores ranged from 0 to 100. Higher scores indicating better HRQL. Analysis was performed using FAS. Here, number of subjects analysed signifies subjects who were evaluable for this endpoint.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Week 12

End point values	Placebo	Ontamalimab 25 mg	Ontamalimab 75 mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	50	104	106	
Units: Score on a Scale				
least squares mean (standard error)				
Physical Functioning: Change at Week 12	3.40 (± 0.901)	5.03 (± 0.657)	3.79 (± 0.646)	
Role-Physical: Change at Week 12	4.47 (± 1.205)	7.39 (± 0.884)	6.90 (± 0.874)	
Bodily Pain: Change at Week 12	5.55 (± 1.293)	8.18 (± 0.941)	7.06 (± 0.926)	
General Health: Change at Week 12	3.93 (± 1.203)	7.00 (± 0.880)	6.34 (± 0.865)	
Vitality: Change at Week 12	3.59 (± 1.381)	8.23 (± 1.008)	7.43 (± 0.993)	

Social Functioning: Change at Week 12	3.59 (± 1.233)	7.43 (± 0.898)	6.54 (± 0.884)	
Role-Emotional: Change at Week 12	1.27 (± 1.317)	5.79 (± 0.958)	5.68 (± 0.944)	
Mental Health: Change at Week 12	3.56 (± 1.268)	7.90 (± 0.925)	6.47 (± 0.911)	

## Statistical analyses

No statistical analyses for this end point

## Secondary: Number of Subjects Based on Inpatient Hospitalization

End point title	Number of Subjects Based on Inpatient Hospitalization
-----------------	---

End point description:

Number of subjects based on inpatient hospitalization due to all-cause hospitalization, gastrointestinal related, Other illness/problem, and undergo gastrointestinal related procedures during the entire study period were reported. FAS consisted of all subjects in the randomized set who had received at least 1 dose of IP.

End point type	Secondary
----------------	-----------

End point timeframe:

From start of study up to follow up (Week 29)

End point values	Placebo	Ontamalimab 25 mg	Ontamalimab 75 mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	56	111	112	
Units: Subjects				
All-Cause Hospitalization	2	3	2	
Gastrointestinal Related	1	2	1	
Other Illness/Problem	1	2	2	
Undergo Gastrointestinal Related Procedures	1	0	0	

## Statistical analyses

No statistical analyses for this end point

## Secondary: Median Duration of Total Inpatient Days

End point title	Median Duration of Total Inpatient Days
-----------------	---

End point description:

Inpatient days were calculated as date of discharge - date of admission + 1. Median duration of total inpatient days during the entire study period was reported. FAS consisted of all subjects in the randomized set who had received at least 1 dose of IP. Here, number of subjects analysed signifies subjects who were evaluable for this endpoint.

End point type	Secondary
----------------	-----------

End point timeframe:

From start of study up to follow-up (Week 29)



<b>End point values</b>	Placebo	Ontamalimab 25 mg	Ontamalimab 75 mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	2	3	2	
Units: Days				
median (full range (min-max))	10.5 (6 to 15)	7.0 (6 to 11)	2.0 (2 to 2)	

### Statistical analyses

---

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

From start of study drug administration up to follow-up (Week 29)

Assessment type	Non-systematic
-----------------	----------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	19.1
--------------------	------

### Reporting groups

Reporting group title	Placebo
-----------------------	---------

Reporting group description:

Subjects received placebo matched to ontamalimab subcutaneous (SC) injection, using a prefilled syringe (PFS) on Week 0, Week 4, and Week 8 in a 12-week treatment period.

Reporting group title	Ontamalimab 25 mg
-----------------------	-------------------

Reporting group description:

Subjects received 25 milligrams (mg) of ontamalimab SC injection, using a PFS on Week 0, Week 4 and Week 8 in a 12-week treatment period.

Reporting group title	Ontamalimab 75 mg
-----------------------	-------------------

Reporting group description:

Subjects received 75 mg of ontamalimab SC injection, using a PFS on Week 0, Week 4 and Week 8 in a 12-week treatment period.

Serious adverse events	Placebo	Ontamalimab 25 mg	Ontamalimab 75 mg
Total subjects affected by serious adverse events			
subjects affected / exposed	4 / 56 (7.14%)	5 / 111 (4.50%)	3 / 112 (2.68%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Cardiac disorders			
Supraventricular tachycardia			
subjects affected / exposed	0 / 56 (0.00%)	1 / 111 (0.90%)	0 / 112 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Headache			
subjects affected / exposed	0 / 56 (0.00%)	1 / 111 (0.90%)	0 / 112 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			

subjects affected / exposed	0 / 56 (0.00%)	1 / 111 (0.90%)	1 / 112 (0.89%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Leukopenia			
subjects affected / exposed	0 / 56 (0.00%)	1 / 111 (0.90%)	0 / 112 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	0 / 56 (0.00%)	0 / 111 (0.00%)	1 / 112 (0.89%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Colitis ulcerative			
subjects affected / exposed	3 / 56 (5.36%)	1 / 111 (0.90%)	1 / 112 (0.89%)
occurrences causally related to treatment / all	0 / 3	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Hydrocalyx			
subjects affected / exposed	1 / 56 (1.79%)	0 / 111 (0.00%)	0 / 112 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Pneumonia			
subjects affected / exposed	0 / 56 (0.00%)	1 / 111 (0.90%)	0 / 112 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Rash pustular			
subjects affected / exposed	0 / 56 (0.00%)	1 / 111 (0.90%)	0 / 112 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	Placebo	Ontamalimab 25 mg	Ontamalimab 75 mg
Total subjects affected by non-serious adverse events			
subjects affected / exposed	7 / 56 (12.50%)	5 / 111 (4.50%)	7 / 112 (6.25%)
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	4 / 56 (7.14%)	2 / 111 (1.80%)	7 / 112 (6.25%)
occurrences (all)	5	2	9
Gastrointestinal disorders			
Nausea			
subjects affected / exposed	4 / 56 (7.14%)	3 / 111 (2.70%)	2 / 112 (1.79%)
occurrences (all)	5	3	3

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
05 September 2018	Protocol Amendment 1: <ul style="list-style-type: none"><li>- Updated exclusion criteria to further define the exclusion of subjects with colitis, a history of positive Mycobacterium tuberculosis (TB), or compromised liver function.</li><li>- Updated exclusion criteria to indicate exclusion of subjects with prior nonbiologic treatment with immunomodulatory properties or prior apheresis or plasma exchange within the specified timeframe.</li><li>- Added a new section to provide appropriate guidance on patients who have been enrolled with elevated liver function test (LFT) values or who experience an increase in LFT(s) during the study.</li></ul>
11 November 2019	Protocol Amendment 2: <ul style="list-style-type: none"><li>- Updated text to reflect preliminary results of an ePPND toxicity study in nonhuman primates, which indicated that, at the dose levels tested (30 mg/kg and 60 mg/kg), infant losses were increased in ontamalimab-exposed animals when compared both to control animals in the study and to the historical control animal data from the testing facility. The relevance of this finding to humans was unknown but could not be excluded.</li><li>- Added text to address FDA recommendation to evaluate the risk of hypersensitivity reactions in the Phase 3 studies and aid in the collection of relevant safety data.</li></ul>

Notes:

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

The study was terminated as per the sponsor decision to discontinue the SHP647 (ontamalimab) clinical trial development program for inflammatory bowel diseases (IBD) early.

Notes: